Clinically significant gastrointestinal bleeding within 6 months prior to the first dose of ALRN-6924
Ongoing, clinically significant bleeding (CTCAE grade 3 or 4)
Known or suspected clinically significant active bleeding.
History of clinically significant bleeding or known platelet or coagulation disorder
Patients with history of clinically significant bleeding disorder
Patients with clinically significant unexplained bleeding within 28 days prior to entering the study
History or evidence of bleeding disorder or active clinically significant bleeding requiring medical intervention.
History of clinically significant bleeding
No clinically significant gastrointestinal bleeding within 24 weeks before the first dose of study treatment
Any sign of clinically significant bleeding
Bleeding diathesis including clinically significant platelet disorders or active hemoptysis (defined as bright red blood of ? 1/2 teaspoon [2.5 mL] in any 24 hour period) within 6 months prior to study day 1. For clinically significant epistaxis within 4 weeks prior to study day 1, no risk of further bleeding must be clearly documented.
Clinically significant gastrointestinal bleeding within 6 months prior to the first dose of ALRN-6924
History of active clinically significant bleeding
Clinically significant bleeding within 14 days of Cycle 1 Day 1 (Treatment Groups B and C only).
Clinically significant bleeding within 28 days of Cycle 1 Day 1
Patients with clinically significant unexplained bleeding within 28 days prior to entering the study
PART B: History of clinically significant bleeding disorder
History of clinically significant bleeding episodes
Documented or known clinically significant bleeding disorder.
History of clinically significant bleeding within 6 months of enrollment/randomization
Patients must not have a known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhages in the past
Patients with clinically significant unexplained bleeding within 28 days prior to entering the study
Patients with clinically significant unexplained bleeding within 28 days prior to entering the study
Any sign of clinically significant bleeding
Clinically significant bleeding within 30 days before enrollment
Clinically significant bleeding within 28 days of study Day 1
Clinically significant gastrointestinal bleeding occurring <= 4 weeks prior to randomization
Have active, acute, or chronic clinically significant infections or bleeding.
History of clinically significant bleeding within 6 months of enrollment/randomization
Patients with clinically significant unexplained bleeding within 28 days prior to entering the study
Patient has acute bleeding that is clinically significant within 24 hours before the start of study treatment.